Personalis SG&A Expenses 2018-2024 | PSNL

Personalis sg&a expenses from 2018 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Personalis Annual SG&A Expenses
(Millions of US $)
2024 $46
2023 $50
2022 $64
2021 $48
2020 $34
2019 $22
2018 $11
2017 $10
Personalis Quarterly SG&A Expenses
(Millions of US $)
2024-12-31 $11
2024-09-30 $11
2024-06-30 $12
2024-03-31 $12
2023-12-31 $12
2023-09-30 $12
2023-06-30 $12
2023-03-31 $14
2022-12-31 $18
2022-09-30 $15
2022-06-30 $16
2022-03-31 $15
2021-12-31 $14
2021-09-30 $12
2021-06-30 $11
2021-03-31 $10
2020-12-31 $11
2020-09-30 $8
2020-06-30 $8
2020-03-31 $7
2019-12-31 $6
2019-09-30 $6
2019-06-30 $5
2019-03-31 $4
2018-12-31
2018-09-30 $3
2018-06-30 $3
2017-12-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.367B $0.085B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) IL $18.357B 6.72
Dr Reddy's Laboratories (RDY) IN $11.687B 22.29
BridgeBio Pharma (BBIO) US $7.324B 0.00
Bausch Health Cos (BHC) CA $2.003B 1.45
Supernus Pharmaceuticals (SUPN) US $1.839B 17.10
Amphastar Pharmaceuticals (AMPH) US $1.164B 7.04
Taysha Gene Therapies (TSHA) US $0.529B 0.00
Assembly Biosciences (ASMB) US $0.108B 0.00
Sol-Gel Technologies (SLGL) IL $0.020B 0.00
Evoke Pharma (EVOK) US $0.005B 0.00
Teligent (TLGT) US $0.000B 0.00